Psilocybin therapy for treatment-resistant depression

October 23, 2018

COMPASS Pathways Receives FDA Breakthrough Therapy Designation for Psilocybin Therapy for Treatment-resistant Depression

COMPASS Pathways, a life sciences company determined to develop cures for treatment-resistant depression based on psilocybin now received “Breakthrough Therapy designation” by the Food and Drug Administration – putting them on the Fast Track to have their psilocybin therapy approved.

Leave a Reply

Your email address will not be published. Required fields are marked *